UnitedHealth UNH Stock Reclaims $300 on Dividend and Berkshire Boost – Trend Shift?
Due to Berkshire Hathaway's most recent 13F disclosure, UnitedHealth's stock is experiencing an after-hours rise that is reviving investor..
Quick overview
- Berkshire Hathaway's recent 13F filing revealed a significant investment in UnitedHealth, purchasing over five million shares worth approximately $1.6 billion.
- Despite a mixed Q2 earnings report with revenue growth overshadowed by rising medical costs, UnitedHealth's stock rebounded to $300 following Berkshire's disclosure.
- The company confirmed a $2.21 per share cash dividend, contributing to an 11% rally in its stock amidst broader market concerns.
- Market sentiment has improved with Buffett's backing, but challenges related to cost control and regulatory scrutiny remain.
Due to Berkshire Hathaway’s most recent 13F disclosure, UnitedHealth’s stock is experiencing an after-hours rise that is reviving investor confidence following weeks of legal issues, disappointing earnings, and internal controversy.
Berkshire’s Strategic Move
Berkshire Hathaway’s second-quarter 13F filing unveiled major portfolio reshuffling, most notably sizable acquisitions in UnitedHealth and Chevron. Under CEO Warren Buffett, the firm disclosed that as of June 30 it had purchased just over five million UnitedHealth shares, worth about $1.6 billion. At the time, shares traded near $300.
UNH Chart Weekly – Can This Rebound Change the Declining Trend?
Following UnitedHealth’s Q2 earnings miss in July, that investment briefly slipped underwater — but today’s disclosure has sent the stock right back to $300, placing Buffett’s stake at breakeven.
Q2 Earnings: Revenue Growth Meets Cost Pressures
UnitedHealth’s second-quarter results painted a mixed picture. While several core business divisions posted strong revenue gains year-over-year, earnings per share fell well short of expectations. The main culprit: surging medical costs, which eroded margins and overshadowed solid performances at Optum Rx and in domestic commercial membership growth.
Investors have grown increasingly concerned that rising expenses are outpacing pricing adjustments. Margin compression, a worsening medical cost ratio, and lowered earnings guidance have amplified these fears — despite the company still projecting revenue growth in 2025.
Dividend Support and Market Sentiment
UnitedHealth recently confirmed a $2.21 per share cash dividend, which may have helped underpin last week’s 11% rally. This came during a relatively quiet broader market session, as inflation jitters lingered following a hotter-than-expected Producer Price Index reading. For some investors, the dividend reinforced confidence in the company’s stability during a turbulent period.
Looking Ahead
With Berkshire Hathaway’s seal of approval now public, market sentiment has shifted sharply. While challenges remain — particularly around cost control and regulatory scrutiny — Buffett’s investment may act as a psychological anchor for shareholders. The coming quarters will reveal whether this rebound is the start of a sustained recovery or just a temporary reprieve.
- Check out our free forex signals
- Follow the top economic events on FX Leaders economic calendar
- Trade better, discover more Forex Trading Strategies
- Open a FREE Trading Account
Save